Treatment of autoimmune diseases is the theme of the already fifth Regional BioCamp
- Lek, a Sandoz company, is organising a top science event for the best science students from the region – Regional BioCamp 2015, which will be held from 17 – 19 May, now for the fifth year in a row.
- The Regional BioCamp successfully links science and economy and opens the door to new knowledge and innovative thinking for the future. It confirms the focus of Sandoz in Slovenia on investing in the development and long-term support for young talents.
- This year, the lecturers and participants will discuss new strategies of treatment of autoimmune diseases, focusing on rheumatoid arthritis, the most common autoimmune disease.
On Sunday, 35 top science students from the region will once again gather in Ljubljana to discuss new strategies for treatment of autoimmune diseases with speakers and mentors at the Regional BioCamp 2015. Lek, a Sandoz company, which has been organising this top science event for five consecutive years, will have hosted in Slovenia a total of 175 of the most promising students from the region.
The Regional BioCamp enables the most promising science students to get a first-hand glimpse of the world of pharmacy and to meet experienced experts and managers. This year, university students from 13 countries are participating at the Regional BioCamp: Slovenia, Austria, Bosnia and Herzegovina, Denmark, Croatia, Ireland, Italy, Macedonia, Germany, Poland, Russia, Serbia, and Great Britain. Out of a total of more than 120 entries the Sandoz experts selected 35 of the best that will have the opportunity to meet some of the leading experts from Lek, Sandoz and Novartis and also present their knowledge and innovative thinking.
This year on autoimmune diseases
Patients are at the heart of the modern pharmaceutical industry, and every year this is a key guideline for the selection of topics for the Regional BioCamp. Every year, a new theme is presented, but patients are always our main focus. This year, speakers and participants will discuss new strategies for the treatment of autoimmune diseases, with a focus on rheumatoid arthritis, the most common autoimmune disease.
In addition to autoimmune diseases, the Regional BioCamp 2015 will also highlight business innovation, innovation in the generic pharmaceutical and biopharmaceutical industry, global experience in the field of development of biosimilars, the patient’s view on rheumatoid arthritis treatment options, opportunities for career development and how to start up and run your own business.
- Dr. Karin Klokkers, Chief Scientific Officer at Sandoz
- Prof. Dr. Peter Olesen, Chairman of the European Institute of Innovation & Technology Governing Board
- Dr. Joerg Windisch, Chief Science Officer at Biofarmaceuticals Sandoz
- Prof. Dr. Borut Božič, Dean at Faculty of Pharmacy, University of Ljubljana
- Dr. Wolfgang Hueber, Director, Discovery and Profiling, Novartis Institutes for Biomedical Research
- Prof. Dr. Matija Tomšič, Head of clinical department of rheumatology, University Medical Center Ljubljana
- Aladar Belec, a patient with rheumatoid arthritis
- Jakob Šušterič, Director Mesi d.o.o.
The winners of the Regional BioCamp will participate at the Novartis global BioCamp.
Eight winners of the previous four Regional BioCamps have already joined the most promising students from universities from all around the globe at Novartis global BioCamps in Basel. Additionally, a number of students from Slovenia participated at the BioCamp in Basel even before the introduction of the Regional BioCamp. Among participants from Slovenia we can boast two winners at the global level – dr. Ljerka Lah and Janko Ignjatović.
The winners of the Regional BioCamp 2015 will participate at the BioCamp in Basel.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/en.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32